JPS61272655A - Quantitative discrimination method for platelet agglutination power - Google Patents

Abstract

PURPOSE:To make possible the exact quantitative determination of the platelet agglutination power suitable for discrimination, etc. of the therapeutic effect of the cerebral infraction by measuring the agglutination patterns of the platelet by the concn. of a reagent for the platelet agglutination by using the platelets of m,any normal persons, forming a standard agglutination curve group and comparing the curve group and the agglutination curve with respect to the patient's reagent quantity. CONSTITUTION:An adenosine diphosphate (ADP) is added to the platelets of many normal persons within the 0.5-20mu mole range by changing said range at very slight intervals and 30 platelet agglutination patterns corresponding to the respective concns. are measured. The standard curve group with the ADP quantity as a parameter is obtd. from such data as the mathematical expression curve group of the time (unit in minute) after the addition of the ADP and light transmittivity (%) P. The patient's platelet agglutination power is first measured in 4 ways of the equal-ratio intervals within 0.5-20mu mole ADP and is compared with the above-mentioned standard curve group. Said power is then measured with 4 ways of the reagent quantities of equal-ratio intervals between the two points exclusive of the two little and too much reagent. The fine adjustment of the reagent quantity is further repeated if necessary until the reagent quantity matching the standard curve is known. The patient's platelet agglutination power is thus exactly and quantitatively discriminated.

Description

[Detailed description of the invention] [Industrial field of application] This defense (with regard to the quantitative determination method of platelet aggregation ability)
More specifically, the present invention relates to a method for quantitatively determining area fractional aggregation ability suitable for determining therapeutic effects on cerebral infarction, myocardial infarction, etc., or for therapeutic management.

(Prior art) It is well known that antiplatelet agents are used to treat cerebral infarction, myocardial infarction, and even senile dementia. Testing of plate aggregation ability is widely performed.

[Problems to be Solved by the Invention I] Currently, there is no suitable method for obtaining objective judgment results because the tester's experience and subjectivity influence the judgment of platelet aggregation ability.

[Means for Solving the Problems 1] Therefore, the present invention aims to make it possible to objectively judge the platelet aggregation ability by adding ADP (^denosine Di-Phospha) to plasma collected from white fluid.
te) is added as a reagent and its light transmittance is measured over time. In this case, since different patterns are obtained depending on the amount of ADP, a basic standard aggregation curve group is created and used for quantitative determination of agglutination ability.

[Example] Hereinafter, the configuration of the present invention will be explained with accompanying diagrams. First, for a large number of normal people, a certain amount of A! ``) Determine the surface platelet agglomeration curve for P, define these average patterns, and define this as the standard 2i! for this amount of AI')P!
Spelled out as an agglomeration curve.

Then, by changing AI)PI from too little to proper φ and then from proper to too much, the average pattern of the agglomeration curve corresponding to each ADP amount is determined, and these are collected to determine the amount of AIIP as a parameter. Create a set of standard agglomeration curves with overlapping.

Next, one method of automating agglutination ability determination using a computer will be described. First, in order to simplify the determination process, a standard agglomeration curve is approximately expressed using a mathematical formula.

time 1 (min) (a for light transmittance p (%))
, (i = 1 to 6) as a constant, first-order reaction: p-(1-a1cos'(a2 tnee a3) ) x
(eχp(-a4t:) +as)...(1) Secondary reaction: p=(1-eχl')(aet:)) x(eχl) (-a4t) +a5)...(a
).

By appropriately changing this constant a, 30 types of curves are stored in the computer. If these are represented by curves, it will look like Figure 2, and each curve will have a numerical value y (y-1 to 30
).

Next, by pattern matching the standard curve for normal people and the curve of this formula, we find that the parameter χ for normal people
There is a relationship between (μM01) and the y value of the mathematical curve as follows: y=,4.14χ+2.21 (3), and this equation (3) is stored in the combicoater. For pattern matching, for example, a method of minimizing the sum of squares of deviations between both curves is used.

For agglutination ability determination, 0.5 to 20 μMol of ADP is usually used.
ffl is sufficient, and in order to shorten the determination time, for example, 0.5 to 20μMO+ is used in a geometric sense (ratio: 0.5.1,
7.5, 8.20 μMOI · (4), and obtain each aggregation curve at once.

Assume that these are compared with mathematical curves by pattern matching to obtain mathematical curves y1 to y4.

Then, the corresponding Ar)P amounts χ1 to χ4 can be found from equation (3).

χ is a value that indicates whether the amount of reagent applied to a normal person is too little or too much, so for example, assuming that χ1.χ2 is too little and χ3°χ4 is too much, then 5.8μMO
+ further divide into 5 equal ratios, for example, 2.2.2.8
．． 3.6.4.6. , czMol - Finely adjust the reagent amount as shown in (5), perform the test again, and check whether the reagent amount is appropriate in the same manner as the previous time.

If necessary, make further adjustments to the reagents and retest.

Then, the reagent amount for the final test is set as χp1 to χp4, and the mathematical curve Vl) is calculated by pattern matching.
Assume that t~yp4 is obtained and IC.

The reagent amounts .chi.nl to .chi.n4 for a normal person can be determined by the above equation (3), and all of these .chi. should be close to appropriate amounts. Therefore, −χpi/χn1 (i=l, 2.3.4)...
(6) Calculate ■, and use the average value of as the patient's platelet aggregation ability.

ni=-(to 1+ to 2+ to 3+ to 4)... (7) Niku 1 is agglutinated with less reagent cloth than normal concentration, and K>1 is the opposite.

In order to express this in easy-to-read numbers, the logarithmic platelet aggregation coefficient I P A C (logarith+l1ic
Plateel＾grigability Coef
ficient) is defined by the following equation.

1-PAC-[-0,+0.5 to 45Jog]...(
8) However, W is a Gauss symbol and represents the largest integer not exceeding W.

As a result, it becomes possible to display the aggregation ability in easy-to-read numerical values using the coefficients in the table below.

[Advantageous Effects of the Invention 1] As is clear from the above explanation, according to the method for determining platelet aggregation ability of the present invention, cerebral infarction is detected.

There is an advantage that the effectiveness of antiplatelet agents used in the treatment of myocardial infarction, senile dementia, etc. can be determined and the treatment managed reliably and easily.

[Brief explanation of the drawing]

Figure 1 shows a platelet aggregation curve showing the change in light transmittance over time when AI)P is added to the platelet as a reagent.
In fact, FIG. 2 shows a mathematical curve group simulating the standard agglomeration curve group.餉-yu 9 1do, j-ninri 15 (warishikzE5D

Claims (1)

[Claims] (1) A method for quantitatively determining platelet aggregation ability by performing the following operations (a), (b), (c), (d), and (e). (a) Obtain platelet aggregation curves for a certain amount of reagent for a large number of normal subjects, determine the average pattern of these and use it as a standard aggregation curve for that reagent amount, and finely adjust the reagent amount from too little to an appropriate amount to too much. The average pattern of the agglutination curve corresponding to each amount is determined, and these are collected to create a standard agglutination curve group using the reagent amount as a parameter. (b) Next, determine the patient's agglutination curve for one or more reagent amounts, select the standard curve with the pattern closest to the patient's agglutination curve from the group of standard agglutination curves, and determine whether it is too small based on the parameters for it. Determine whether the amount is too much, increase the amount of reagent appropriately if it is too much, decrease it if it is too much, and obtain the patient's agglutination curve for one or more reagent amounts again. (c) Furthermore, in the same way as last time, compare the agglutination curve with the standard curve, determine the standard agglutination curve with the closest pattern, find out whether the corresponding parameter is too small or too large, and adjust the reagent amount again. , perform the inspection again. (d) By repeating the test in the same manner, the patient's platelet aggregation curve becomes a pattern close to the standard curve of the appropriate dose parameter in the standard aggregation curve group. (e) By comparing the amount of reagent at this time with the parameters of the standard curve, the degree of enhancement, normality, or inhibition of the patient's platelet aggregation ability is quantitatively determined.